Sonoma Pharmaceuticals (NASDAQ:SNOA) Stock Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA)’s stock price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.78 and traded as high as $2.60. Sonoma Pharmaceuticals shares last traded at $2.55, with a volume of 19,093 shares traded.

Sonoma Pharmaceuticals Stock Up 3.1 %

The firm’s 50-day moving average is $2.81 and its two-hundred day moving average is $1.80. The stock has a market cap of $3.52 million, a P/E ratio of -0.53 and a beta of 1.43.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 1.95% of the stock is currently owned by institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.